Sunday, March 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Quick COVID Breathalyzer Could Allow Mass Screening in Public Places

by Global Biodefense Staff
February 2, 2022
Quick COVID Breathalyzer Could Allow Mass Screening in Public Places

A SERS-based breathalyzer can distinguish volatile organic compounds in the breath of COVID-positive people in less than 5 minutes. Credit: Shi Xuan Leong and Yong Xiang Leong, Nanyang Technological University

According to experts, bringing an end to the pandemic will require rapid screening of people attending large gatherings, such as conferences and weddings. Even those who are asymptomatic can still transmit COVID-19 to others, making it important to identify and isolate them until they are no longer contagious. Now, researchers reporting in ACS Nano have developed a prototype “breathalyzer” that can sensitively and accurately diagnose COVID-19, even in asymptomatic individuals, in less than 5 minutes.

Currently, the “gold standard” for COVID-19 testing is a technique called reverse transcription-polymerase chain reaction (RT-PCR), which is slow, requires an uncomfortable nasopharyngeal swab for sample collection and must be performed in a lab. The rapid antigen test is much quicker but has a higher rate of false negatives and positives. Scientists have also developed breathalyzer-type tests for COVID-19, which rely on differences in concentrations of volatile organic compounds exhaled by those infected with the coronavirus, but most require bulky, nonportable instruments for analysis. Xing Yi Ling and colleagues wanted to develop a quick, convenient and accurate breathalyzer test that would be suitable for on-site screening of large numbers of people.

The researchers designed a handheld breathalyzer that contains a chip with three surface-enhanced Raman scattering (SERS) sensors attached to silver nanocubes. When a person exhales into the device for 10 seconds, compounds in their breath chemically interact with the sensors. Then, the researchers load the breathalyzer into a portable Raman spectrometer that characterizes the bound compounds based on changes to the molecular vibrations of the SERS sensors.

The team found that Raman spectra from COVID-positive and -negative people were different in regions responsive to ketones, alcohols and aldehydes, which they used to develop a statistical model for COVID diagnosis. They tested the breathalyzer on 501 people in hospitals and airports in Singapore, who were shown by RT-PCR to be negative (85.2%), positive and symptomatic (8.6%), or positive and asymptomatic (6.2%) for the coronavirus. The method had a 3.8% false-negative and 0.1% false-positive rate, comparable to RT-PCR tests, but it could be completed on-site in less than 5 minutes. The breathalyzer could someday be a new tool to reduce the silent spread of COVID-19 in communities, the researchers say.

Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min. ACS Nano, 18 January 2022.

ABSTRACT: Population-wide surveillance of COVID-19 requires tests to be quick and accurate to minimize community transmissions. The detection of breath volatile organic compounds presents a promising option for COVID-19 surveillance but is currently limited by bulky instrumentation and inflexible analysis protocol. Here, we design a hand-held surface-enhanced Raman scattering-based breathalyzer to identify COVID-19 infected individuals in under 5 min, achieving >95% sensitivity and specificity across 501 participants regardless of their displayed symptoms. Our SERS-based breathalyzer harnesses key variations in vibrational fingerprints arising from interactions between breath metabolites and multiple molecular receptors to establish a robust partial least-squares discriminant analysis model for high throughput classifications. Crucially, spectral regions influencing classification show strong corroboration with reported potential COVID-19 breath biomarkers, both through experiment and in silico. Our strategy strives to spur the development of next-generation, noninvasive human breath diagnostic toolkits tailored for mass screening purposes.

The authors acknowledge funding from the National Medical Research Council, Singapore, A*STAR Singapore, the Max Planck Institute-Nanyang Technological University Joint Lab and Nanyang Technological University.

Tags: CoronavirusCOVID-19Editor PickInnovationRapid DiagnosticsSARS-CoV-2Spectroscopy

Related Posts

New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
New Virus Discovered in Swiss Ticks
Biosurveillance

New Virus Discovered in Swiss Ticks

December 7, 2022
Why Do Some of the Outbreak Genomes Have More Mutations Than Others?
Biosurveillance

Virginia Institutes Partner to Join National Pathogen Genomics Centers of Excellence Network

October 25, 2022
Researcher holds a pipette
Biodetection

These Nanotech Bubbles Burst When They Detect Viruses in the Air

October 25, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy